Phase I Study of Bevacizumab, Everolimus, and Panobinostat (LBH-589) in Advanced Solid Tumors

Por Strickler, John H., Starodub, Alexander N., Jia, Jingquan, Meadows, Kellen L., Nixon, Andrew B., Dellinger, Andrew, Morse, Michael A., Uronis, Hope E., Marcom, P. Kelly, Zafar, S. Yousuf, Haley, Sherri T., Hurwitz, Herbert I.
Publicado em 2012

Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer

Por Strickler, John H., McCall, Shannon, Nixon, Andrew B., Brady, John C., Pang, Herbert, Rushing, Christel, Cohn, Allen, Starodub, Alexander, Arrowood, Christy, Haley, Sherri, Meadows, Kellen L., Morse, Michael A., Uronis, Hope E., Blobe, Gerard C., Hsu, S. David, Zafar, S. Yousuf, Hurwitz, Herbert I.
Publicado em 2013

A Phase I Trial of the IGF‐1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer

Por Vlahovic, Gordana, Meadows, Kellen L., Hatch, Ace J., Jia, Jingquan, Nixon, Andrew B., Uronis, Hope E., Morse, Michael A., Selim, M. Angelica, Crawford, Jeffrey, Riedel, Richard F., Zafar, S. Yousuf, Howard, Leigh A., O'Neill, Margot, Meadows, Jennifer J., Haley, Sherri T., Arrowood, Christy C., Rushing, Christel, Pang, Herbert, Hurwitz, Herbert I.
Publicado no Oncologist (2018)

A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer

Por Strickler, John H., Rushing, Christel N., Niedzwiecki, Donna, McLeod, Abigail, Altomare, Ivy, Uronis, Hope E., Hsu, S. David, Zafar, S. Yousuf, Morse, Michael A., Chang, David Z., Wells, James L., Blackwell, Kimberly L., Marcom, P. Kelly, Arrowood, Christy, Bolch, Emily, Haley, Sherri, Rangwala, Fatima A., Hatch, Ace J., Nixon, Andrew B., Hurwitz, Herbert I.
Publicado no BMC Cancer (2019)